Research News

Arterial stiffness may be a novel risk factor for metabolic syndrome in teens, a paper published in the American Journal of Physiology-Heart and Circulatory Physiology concludes. The study was conducted in collaboration between the University of Bristol in the UK, the University of Exeter in the UK, and the University of Eastern Finland.

Research molecule of Novartis, Iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naive paroxysmal nocturnal hemoglobinuria patients, as per recent trials.

The trial met its primary endpoint and demonstrated clinically meaningful benefits across secondary endpoints. These data were presented at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT).

Drinking cranberry juice has long been a mythical prevention strategy for women who develop a urinary tract infection – and new medical evidence shows consuming cranberry products is an effective way to prevent a UTI before it gets started.

Researchers at NYU Grossman School of Medicine and Janssen Biotech Inc. have shown in early tests that a bioengineered drug candidate can counter infection with Staphylococcus aureus—a bacterial species widely resistant to antibiotics and a major cause of death in hospitalized patients.

Cancer drugs that stimulate the body’s immune system to attack tumors are a promising way to treat many types of cancer. However, some of these drugs produce too much systemic inflammation when delivered intravenously, making them harmful to use in patients.

Scientists in Melbourne have designed a new type of oral capsule that could mean pain-free delivery of insulin and other protein drugs. Co-lead researcher Professor Charlotte Conn, a biophysical chemist from RMIT University, said protein drugs had proven challenging to deliver orally as the drugs degrade very quickly in the stomach – until now.

Houston Methodist nanomedicine researchers have found a way to tame pancreatic cancer - one of the most aggressive and difficult to treat cancers - by delivering immunotherapy directly into the tumor with a device that is smaller than a grain of rice.

A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy. If confirmed in additional studies, enoblituzumab could become the first promising antibody-based immunotherapy agent against prostate cancer.

The cellular glitches underlying a rare genetic disorder called activated PI3K Delta syndrome 2 (APDS2) have been identified by researchers at the Garvan Institute of Medical Research. The disorder is caused by genetic variations that disrupt immune cell signalling through a protein called PI3K.